Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Thousand Oaks, California
- Most recent report
- 10-Q, filed Nov 5, 2026
- Incorporated
- Delaware
- Filings on record
- 44 filings
- On EDGAR
- CIK 2056611
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
Financials 2
News 3
Prospectuses and Registrations 5
Ownership 8 of 26
- SCHEDULE 13G/A Large holder reported a passive stake, amended Nov 6, 2026
- SCHEDULE 13G Large holder reported a passive stake Oct 29, 2026
- SCHEDULE 13G Large holder reported a passive stake Aug 18, 2026
- SCHEDULE 13D Large holder reported an active stake Aug 17, 2026
- SCHEDULE 13G Large holder reported a passive stake Aug 17, 2026
- SCHEDULE 13G Large holder reported a passive stake Aug 13, 2026
- 4 Insider reported a trade Aug 12, 2026
- 4 Insider reported a trade Aug 12, 2026
Other 8
- EFFECT Notice that a registration became effective Aug 6, 2026
- S-1MEF Aug 6, 2026
- CERT Exchange certified a listing Aug 6, 2026
- 8-A12B Registration of a security for exchange listing Aug 4, 2026
- DRS/A Draft registration statement, submitted confidentially, amended Jun 5, 2026
- DRS/A Draft registration statement, submitted confidentially, amended May 18, 2026
- DRS Draft registration statement, submitted confidentially Mar 27, 2026
- D Feb 13, 2025
Everything here comes from Latigo Biotherapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.